Global Colorectal Cancer Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

November 2017 | 211 pages | ID: G04175922F8EN
Precision Business Insights (PBI)

Abstracts

Colorectal cancer is also known as bowel cancer. It refers to the abnormal growth of the cells in colon and rectum due to cancer. Colorectal cancer starts either in the colon and rectum. Cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain.

Global colorectal cancer market is driven by some of the major factors such as increasing prevalence of colorectal cancer, technological advancements in the cancer therapy, aging population, and raise in consumer awareness about colorectal cancers. However, high costs of screening tests and drugs, lack of knowledge are some of the restraints that are hampering the growth of the global colorectal cancer drugs market.

The global colorectal cancer drugs market is segmented by therapy, drug class, distribution channel, and regions.

On the basis of therapy, global colorectal cancer drugs market is segmented as

• Adjuvant chemotherapy
• Palliative chemotherapy
• Immuno therapy

Neo adjuvant chemotherapy

• On the basis of drug class, global colorectal cancer drugs market is segmented as
• Capecitabine (Xeloda)
• Irinotecan (Camptosar)
• Fluorouracil (5-FU, Adrucil)
• Trifluridine/tipiracil (TAS-102, Lonsurf)
• Oxaliplatin (Eloxatin)
• Others

Some common treatment regimens using these drugs include:

• 5-FU
• Capecitabine, an oral form of 5-FU
• 5-FU with leucovorin (Wellcovorin), a vitamin that improves the effectiveness of 5-FU
• FOLFIRI: 5-FU with leucovorin and irinotecan
• FOLFOX: 5-FU with leucovorin and oxaliplatin
• Irinotecan alone
• XELOX/CAPEOX: Capecitabine with oxaliplatin
• XELIRI/CAPIRI: Capecitabine with irinotecan

On the basis of distribution channel, the global colorectal cancer drugs market is segmented as

• Retail Pharmacies
• Hospital Pharmacies
• Others

Colorectal cancer is the third most common cancer in the world. Huge government initiatives taken by the nations are booming up the growth of the colorectal cancer drugs treatment market globally. Biologics such as Zaltrap (Ziv-Aflibercept), Erbitux (Cetuximab), Avastin (Bevacizumab) are using rapidly for the treatment for colorectal cancer that are used as a targeted therapy and they acts only on the malignant cells. Market players in the colorectal cancer drugs market forming strategic alliances and partnerships to increase their market share.

Geographically, global colorectal cancer treatment market is segmented into five key regions such as Latin America, North America, Asia-Pacific, Europe and The Middle East and Africa. North America expected to grow at significant rate in colorectal cancer drugs market owing to the growing incidence of colorectal cancer and widespread awareness about early diagnosis and treatment of colorectal cancer. Asia Pacific region expected to have rapid growth in the market during the forecast period owing to huge population densities and high incidence of colorectal cancer in countries such as India and China.

Some of the players in the colorectal cancer drugs market are Amgen Inc. (U.S), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), and Sanofi (France) to name a few.

In Aug 2016, Sanofi’s Zaltrap received U.S. FDA approval to use with FOLFIRI to treat adult patients having colorectal cancer

In May 23, 2014, the U.S. Food and Drug Administration (FDA) approved for Amgen’s Vectibix (panitumumab) for use in combination with FOLFOX, to treat metastatic colorectal cancer

In Sept. 16, 2013, Genentech received U.S. FDA approval for the first generic version of Xeloda, to treat cancer of the colorectal cancer

In Sept 2012, The USFDA approved Stivarga (regorafenib) (Bayer) tablets to treat patients with collateral cancer

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL COLORECTAL CANCER DRUGS MARKET INTRODUCTION

2.1. Global Colorectal Cancer Drugs Market– Taxonomy
2.2. Global Colorectal Cancer Drugs Market–Definitions
  2.2.1. Drug Type
  2.2.2. Therapy

3. GLOBAL COLORECTAL CANCER DRUGS MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Colorectal Cancer Drugs Market Dynamics – Factors Impact Analysis
3.6. Global Colorectal Cancer Drugs Market– Recent Market Introductions

4. GLOBAL COLORECTAL CANCER DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL COLORECTAL CANCER DRUGS MARKET FORECAST, BY THERAPY, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Adjuvant Chemotherapy
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Palliative Chemotherapy
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Immuno Therapy
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Neo Adjuvant Chemotherapy
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis

6. GLOBAL COLORECTAL CANCER DRUGS MARKET FORECAST, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Capecitabine
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Irinotecan
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Fluorouracil
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Trifluridine/tipiracil
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis
6.5. Oxaliplatin
  6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.5.3. Market Opportunity Analysis
6.6. Others
  6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.6.3. Market Opportunity Analysis

7. GLOBAL COLORECTAL CANCER DRUGS MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL COLORECTAL CANCER DRUGS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Region, 2017 – 2023

9. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.1.1. Adjuvant Chemotherapy
    9.1.1.2. Palliative Chemotherapy
    9.1.1.3. Immuno Therapy
    9.1.1.4. Neo Adjuvant Chemotherapy
  9.1.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Capecitabine
    9.1.2.2. Irinotecan
    9.1.2.3. Fluorouracil
    9.1.2.4. Trifluridine/tipiracil
    9.1.2.5. Oxaliplatin
    9.1.2.6. Others
  9.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Retail Pharmacies
    9.1.3.2. Hospital Pharmacies
    9.1.3.3. Online Pharmacies
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2017 – 2023
  9.1.6. North America Colorectal Cancer Drugs Market Dynamics – Trends

10. EUROPE COLORECTAL CANCER DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.1.1. Adjuvant Chemotherapy
    10.1.1.2. Palliative Chemotherapy
    10.1.1.3. Immuno Therapy
    10.1.1.4. Neo Adjuvant Chemotherapy
  10.1.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Capecitabine
    10.1.2.2. Irinotecan
    10.1.2.3. Fluorouracil
    10.1.2.4. Trifluridine/tipiracil
    10.1.2.5. Oxaliplatin
    10.1.2.6. Others
  10.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Retail Pharmacies
    10.1.3.2. Hospital Pharmacies
    10.1.3.3. Online Pharmacies
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2017 – 2023
  10.1.6. Europe Colorectal Cancer Drugs Market Dynamics – Trends

11. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.1.1. Adjuvant Chemotherapy
    11.1.1.2. Palliative Chemotherapy
    11.1.1.3. Immuno Therapy
    11.1.1.4. Neo Adjuvant Chemotherapy
  11.1.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Capecitabine
    11.1.2.2. Irinotecan
    11.1.2.3. Fluorouracil
    11.1.2.4. Trifluridine/tipiracil
    11.1.2.5. Oxaliplatin
    11.1.2.6. Others
  11.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Retail Pharmacies
    11.1.3.2. Hospital Pharmacies
    11.1.3.3. Online Pharmacies
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2017 – 2023
  11.1.6. Asia-Pacific Colorectal Cancer Drugs Market Dynamics – Trends

12. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.1.1. Adjuvant Chemotherapy
    12.1.1.2. Palliative Chemotherapy
    12.1.1.3. Immuno Therapy
    12.1.1.4. Neo Adjuvant Chemotherapy
  12.1.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Capecitabine
    12.1.2.2. Irinotecan
    12.1.2.3. Fluorouracil
    12.1.2.4. Trifluridine/tipiracil
    12.1.2.5. Oxaliplatin
    12.1.2.6. Others
  12.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Retail Pharmacies
    12.1.3.2. Hospital Pharmacies
    12.1.3.3. Online Pharmacies
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2017 – 2023
  12.1.6. Latin America Colorectal Cancer Drugs Market Dynamics – Trends

13. MIDDLE EAST & AFRICA COLORECTAL CANCER DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.1.1. Adjuvant Chemotherapy
    13.1.1.2. Palliative Chemotherapy
    13.1.1.3. Immuno Therapy
    13.1.1.4. Neo Adjuvant Chemotherapy
  13.1.2. Drug Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Capecitabine
    13.1.2.2. Irinotecan
    13.1.2.3. Fluorouracil
    13.1.2.4. Trifluridine/tipiracil
    13.1.2.5. Oxaliplatin
    13.1.2.6. Others
  13.1.3. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Retail Pharmacies
    13.1.3.2. Hospital Pharmacies
    13.1.3.3. Online Pharmacies
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Colorectal Cancer Drugs Market- Opportunity Analysis Index - By Therapy, By Drug Type, By End User, and Country, 2017 – 2023
  13.1.6. MEA Colorectal Cancer Drugs Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Amgen Inc. (U.S)
  14.2.2. Bristol-Myers Squibb Company (U.S.)
  14.2.3. F. Hoffmann-La Roche Ltd. (Switzerland)
  14.2.4. Bayer AG (Germany)
  14.2.5. Merck & Co., Inc. (U.S.)
  14.2.6. Sanofi (France)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS